Multi-Purpose Solution
Showing 26 - 50 of >10,000
Osteo Arthritis Knee, Osteoarthritis Trial in United States (Total Knee Replacement)
Active, not recruiting
- Osteo Arthritis Knee
- Osteoarthritis
- Total Knee Replacement
-
Baltimore, Maryland
- +4 more
Jan 23, 2023
Contact Lens Wear Trial in Pittsburg (Complete MPS, NNR06)
Completed
- Contact Lens Wear
- Complete MPS
- NNR06
-
Pittsburg, KansasKannarr EyeCare
Feb 4, 2022
Motoric Cognitive Risk Syndrome, Mild Cognitive Impairment, Aging Trial in Beijing (Ginkgo Leaf Extract and Armillariella Mellea
Recruiting
- Motoric Cognitive Risk Syndrome
- +3 more
- Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
- Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital
Dec 7, 2021
Obstructive Hypertrophic Cardiomyopathy (oHCM) Trial (Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match
Not yet recruiting
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- +3 more
- (no location specified)
Mar 2, 2023
Optivantage Multi-use When Injecting Contrast Media for Contrast
Not yet recruiting
- Patient Participation
- CT examination
- (no location specified)
Sep 8, 2022
Elevated Intraocular Pressure Trial in United States (Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic
Active, not recruiting
- Elevated Intraocular Pressure
- Latanoprost ophthalmic solution, 0.005%
- TC-002 latanoprost ophthalmic solution, 0.005%
-
Garden Grove, California
- +19 more
May 23, 2022
Dry Eye, Dry Eye Syndromes Trial in Memphis (Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution)
Completed
- Dry Eye
- Dry Eye Syndromes
- Reproxalap Ophthalmic Solution (0.25%)
- Vehicle Opthalmic Solution
-
Memphis, TennesseeUniversity Clinical Health
Mar 28, 2022
Neurotrophic Keratitis Trial (BRM424 Ophthalmic Solution, Vehicle)
Not yet recruiting
- Neurotrophic Keratitis
- BRM424 Ophthalmic Solution
- Vehicle
- (no location specified)
Jun 28, 2023
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye Trial
Not yet recruiting
- Primary Open Angle Glaucoma (POAG)
- +3 more
- Experimental: QLS-111 ophthalmic solution, (0.015%)
- +4 more
- (no location specified)
Aug 30, 2023
Colonoscopy Trial in Chendu (100 ml lactulose combined with 1 L PEG, 100 ml lactulose combined with 2 L PEG, 200 ml lactulose)
Completed
- Colonoscopy
- 100 ml lactulose combined with 1 L PEG
- +3 more
-
Chendu, Sichuan, Chinawest china fourth hospital of Sichuan university
Dec 29, 2022
A Multi-center,Prospective, OS to Evaluate Effectiveness of
Completed
- Chronic Obstructive Pulmonary Disease
-
Seoul, Korea, Republic ofThe Konkuk University medical center
Feb 1, 2023
Androgenetic Alopecia, Female Pattern Baldness Trial (Minoxidil Tablets, Minoxidil Topical, Placebo oral tablet)
Not yet recruiting
- Androgenetic Alopecia
- Female Pattern Baldness
- Minoxidil Tablets
- +3 more
- (no location specified)
Jun 2, 2023
Dry Eye Trial in Andover (Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution)
Completed
- Dry Eye
- Reproxalap Ophthalmic Solution (0.25%)
- Vehicle Ophthalmic Solution
-
Andover, MassachusettsAndover Eye Associates
Dec 8, 2021
Gastrointestinal Cancer Trial in China (Nutrition Emulsion (TPF-T), Foods for special medical purposes [FSMP] for patients with
Enrolling by invitation
- Gastrointestinal Cancer
- Nutrition Emulsion (TPF-T)
- Foods for special medical purposes [FSMP] for patients with tumors
-
Beijing, China
- +13 more
Jan 18, 2023
COVID-19 Trial in London (ALG-097558, Placebo, Midazolam)
Not yet recruiting
- COVID-19
- ALG-097558
- +6 more
-
London, United KingdomHammersmith Medicines Research
Apr 21, 2023
Dry Eye Disease Trial (BRM421 Ophthalmic Solution, Vehicle)
Not yet recruiting
- Dry Eye Disease
- BRM421 Ophthalmic Solution
- Vehicle
- (no location specified)
Jan 13, 2023
Alopecia, Androgenetic Trial in Portland, Austin, Norfolk (TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle
Not yet recruiting
- Alopecia, Androgenetic
- TDM-105795, 0.0025%
- +2 more
-
Portland, Oregon
- +2 more
Mar 26, 2023
Presbyopia, Near Vision, Miosis Trial in Chandler, Glendale (Aceclidine+Brimonidine combination ophthalmic solution, Placebo,
Recruiting
- Presbyopia
- +3 more
- Aceclidine+Brimonidine combination ophthalmic solution
- +2 more
-
Chandler, Arizona
- +1 more
Mar 2, 2023
Motor Neuron Disease, Amyotrophic Lateral Sclerosis Trial in United Kingdom (Memantine Hydrochloride Oral Solution, Trazodone
Recruiting
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Memantine Hydrochloride Oral Solution
- +2 more
-
Aberdeen, United Kingdom
- +7 more
May 10, 2022
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy Trial in Philadelphia (Netarsudil 0.02% Ophthalmic Solution
Not yet recruiting
- Rhegmatogenous Retinal Detachment
- Proliferative Vitreoretinopathy
- Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
- Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
-
Philadelphia, PennsylvaniaWills Eye Physicians - Mid Atlantic Retina
Dec 13, 2022
Dry Eye Disease Trial in Andover, Raynham, Memphis (ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution)
Completed
- Dry Eye Disease
- ST-100 Ophthalmic Solution
- Placebo Ophthalmic Solution
-
Andover, Massachusetts
- +2 more
Feb 22, 2022
Small Bowel Obstruction Trial in London (Gastrogra?n, Saline solution (control treatment))
Recruiting
- Small Bowel Obstruction
- Gastrografin
- Saline solution (control treatment)
-
London, Ontario, CanadaChildren's Hospital, London Health Sciences Centre
Apr 5, 2022
Mydriasis Trial in Austin, San Antonio (Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo)
Completed
- Mydriasis
- Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
- Placebo
-
Austin, Texas
- +1 more
Mar 16, 2022